EUVIMEDEUVIMED entdecken
Crossref

A novel rhein derivative Y01 inhibits hepatocellular carcinoma by inducing apoptosis through regulating PI3K/AKT/mTOR pathway

Mingyu Ji, Mulan Li, Zhihong Zhou, Limei Yang, Dong Ran, Tingting Yang, Lele Yang, Wei Tian, Peilin Yang iD

Journal of Pharmacy and Pharmacology · 05.03.2026 · 78 (3)

DOI: 10.1093/jpp/rgaf120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 03.12.2025. Verfasst von Mingyu Ji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Special Biomedicine; School of Medicine, Guangxi University, No. 100 East Daxue Road, Xixiangtang District, Nanning, Guangx…. Hauptthemen laut MEDLINE: Apoptosis, Anthraquinones, TOR Serine-Threonine Kinases, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Open Research Project from Key Laboratory of Prevention and Control of Highly Prevalent Diseases, Innovation Project of Guangxi Graduate Education, Key Laboratory of Basic Research on Regional Diseases (Guangxi Medical University), Education Department of Guangxi Zhuang Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study was to evaluate the novel rhein derivative Y01 for its anti-HCC activity and potential molecular mechanisms, thereby positioning it as a promising candidate for HCC therapy.

Methods

CCK-8, EdU incorporation and clone formation assay were employed to assess the impact of Y01 on the cell viability and proliferation of HCC cells. While apoptosis was assessed through flow cytometry and western blotting techniques. Additionally, the impact of Y01 on cell mobility was evaluated via wound healing and transwell migration assays, with western blotting analyses providing further insights. Mechanistically, transcriptomics and western blotting assays were used to explore the potential signaling pathways.

Results

Y01 markedly suppressed the growth, colony formation, and migratory capacity of HCC cells, induced apoptosis and affected the expression of apoptosis-related proteins. Transcriptomics initially pointed toward the PI3K/AKT/mTOR pathway as a potential target, which was corroborated by western blotting results showing decreased levels of phosphorylated PI3K, AKT, and mTOR following Y01 treatment, highlighting its role in mediating the compound’s anticancer effects.

Conclusions

Y01 inhibited the proliferation, migration, and induced apoptosis of HCC cells possibly by blocking PI3K/AKT/mTOR signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisAnthraquinonesTOR Serine-Threonine KinasesCarcinoma, HepatocellularLiver NeoplasmsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesAntineoplastic AgentsHumansSignal TransductionCell ProliferationCell MovementCell Line, TumorCell SurvivalHep G2 Cells

Stichwörter der Autor:innen

PI3K/AKT/mTORapoptosishepatocellular carcinomarhein derivative

Substanzen

AnthraquinonesTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMTOR protein, humanPhosphatidylinositol 3-KinasesrheinAntineoplastic Agents

Autor:innen und Institutionen

  • Guangxi Key Laboratory of Special Biomedicine; School of Medicine, Guangxi University, No. 100 East Daxue Road, Xixiangtang District, Nanning, Guangxi Zhuang Autonomous Region 530004, China.
  • The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region 530021, China.
  • Department of Medicine Laboratory, The Eighth People's Hospital of Nanning, No. 63 West Mingxiu Road, Xixiangtang District, Nanning, Guangxi Zhuang Autonomous Region 530003, China.
  • Guangxi International Zhuang Medicine Hospital, No. 8 Qiuyue Road, Liangqing District, Nanning, Guangxi Zhuang Autonomous Region 530201, China.
  • Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening, Key Laboratory of Micro-Nanoscale Bioanalysis and Drug Screening of Guangxi Education Department, State Key Laboratory of Targeting Oncology, P…
  • Key Laboratory of Basic Research on Regional Diseases of Education Department of Guangxi Zhuang Autonomous Region, Guangxi Medical University, No. 22 Shuangyong Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous…

ORCID-Profile: Peilin Yang

Förderung

  • Open Research Project from Key Laboratory of Prevention and Control of Highly Prevalent Diseases
  • Innovation Project of Guangxi Graduate Education
  • Key Laboratory of Basic Research on Regional Diseases (Guangxi Medical University), Education Department of Guangxi Zhuang Autonomous Region
  • Guangxi Key Laboratory of Pharmaceutical Precision Detection and Screening
  • Natural Science Foundation of Guangxi Zhuang Autonomous Region

Zitieren

APA

Ji, M., Li, M., Zhou, Z., Yang, L., Ran, D., Yang, T., Yang, L., Tian, W., & Yang, P. (2026). A novel rhein derivative Y01 inhibits hepatocellular carcinoma by inducing apoptosis through regulating PI3K/AKT/mTOR pathway. Journal of Pharmacy and Pharmacology, 78(3). https://doi.org/10.1093/jpp/rgaf120

Vancouver

Ji M, Li M, Zhou Z, Yang L, Ran D, Yang T, et al. A novel rhein derivative Y01 inhibits hepatocellular carcinoma by inducing apoptosis through regulating PI3K/AKT/mTOR pathway. Journal of Pharmacy and Pharmacology. 2026;78(3). doi:10.1093/jpp/rgaf120

BibTeX
@article{Ji2026,
  author = {Ji, Mingyu and Li, Mulan and Zhou, Zhihong and Yang, Limei and Ran, Dong and Yang, Tingting and Yang, Lele and Tian, Wei and Yang, Peilin},
  title = {A novel rhein derivative Y01 inhibits hepatocellular carcinoma by inducing apoptosis through regulating PI3K/AKT/mTOR pathway},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  volume = {78},
  number = {3},
  doi = {10.1093/jpp/rgaf120}
}
Kostenlos starten →